CardioComm Secures TSXV Approval for $512K Loan Facility

Toronto, Ontario — CardioComm Solutions, Inc. (TSXV: EKG) has received approval from the TSX Venture Exchange for a previously announced loan agreement dated November 3, 2025, providing aggregate funding of CA$512,000. The financing will support completion and commercialization of the company’s upcoming “Flagship Product”—its GEMS FLEX and 14‑day Holter/Long‑Term Continuous Monitoring ECG software platform—poised to be a major revenue driver. As part of the agreement, CardioComm issued 345,600 bonus common shares and 6,912,000 warrants to lenders, including insiders, with each warrant exercisable at CA$0.05 until November 3, 2030. The transaction is classified as a “related‑party transaction” under Multilateral Instrument 61‑101, but qualifies for certain exemptions. With the funding secured and TSXV approval in place, CardioComm is advancing toward its target of launching a commercially ready remote ECG analysis solution for healthcare professionals and patients alike. #CardioComm #MedicalTech #ECGMonitoring #TSXV #SlimScan #GrowthStocks #CANSLIM